Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 3/20 | 0.38 |
| ▸ | MC5R | P33032 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | MC1R | Q01726 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | PEPD | P12955 | 2/20 | 0.37 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26210874 | 0.88 | DPP4 (0.52) | ATMMMP2CYP3A4DPP4PEPD | |
| SCHEMBL26210824 | 0.88 | CYP3A4 (0.47) | ATMMMP2CYP3A4MC4RMC5R | |
| Trifluoroacetic Acid SCHEMBL30574559 | 0.83 | DPP4 (0.48) | ATMMMP2DPP4 | |
| SCHEMBL30574558 | 0.81 | CACNA1B (0.44) | MMP2P2RX3 | |
| SCHEMBL26210944 | 0.79 | ALDH1A1 (0.47) | DPP4 | |
| SCHEMBL26439623 | 0.77 | PRSS1 (0.44) | ATMMMP2DPP4PEPDXPNPEP1 | |
| SCHEMBL26439510 | 0.77 | ENPP2 (0.43) | ATMCYP3A4MC4RMC5RMC3R | |
| SCHEMBL26211357 | 0.77 | ENPP2 (0.43) | ATMCYP3A4MC4RMC5RMC3R | |
| SCHEMBL20446655 | 0.76 | MMP2 (0.46) | ATMMMP2CYP3A4 | |
| SCHEMBL20446654 | 0.76 | MMP2 (0.46) | ATMMMP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | ATM 2618/4885MMP2 315/4885CYP3A4 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.